Strs Ohio Has $8.54 Million Stake in IDEXX Laboratories, Inc. $IDXX

Strs Ohio grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,929 shares of the company’s stock after buying an additional 1,929 shares during the quarter. Strs Ohio’s holdings in IDEXX Laboratories were worth $8,543,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of IDEXX Laboratories by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock valued at $4,139,001,000 after buying an additional 146,427 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in IDEXX Laboratories by 71.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after purchasing an additional 825,965 shares in the last quarter. Invesco Ltd. raised its position in IDEXX Laboratories by 0.5% in the first quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock worth $489,832,000 after purchasing an additional 5,418 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in IDEXX Laboratories by 37.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock worth $452,046,000 after purchasing an additional 290,551 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of IDEXX Laboratories by 7.2% in the 1st quarter. American Century Companies Inc. now owns 867,992 shares of the company’s stock worth $364,513,000 after buying an additional 58,178 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $629.51 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The firm has a market cap of $50.36 billion, a PE ratio of 52.42, a price-to-earnings-growth ratio of 4.06 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The business has a fifty day moving average of $637.89 and a 200-day moving average of $568.60.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. UBS Group assumed coverage on IDEXX Laboratories in a report on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 target price for the company. BTIG Research increased their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Stifel Nicolaus upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and increased their target price for the stock from $640.00 to $700.00 in a research report on Friday. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $662.50.

Insiders Place Their Bets

In related news, EVP Michael G. Erickson sold 406 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Lane sold 8,411 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the sale, the executive vice president directly owned 7,132 shares of the company’s stock, valued at $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 54,057 shares of company stock valued at $34,293,468 over the last quarter. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.